A Comprehensive Look at the Metabolomics Market Growth and Key Developments
The global metabolomics market is undergoing significant growth, with the market size valued at USD 2.83 billion in 2023 and projected to reach approximately USD 11.32 billion by 2034, at a robust compound annual growth rate (CAGR) of 13.43% from 2024 to 2034. This surge in market demand can largely be attributed to the growing importance of metabolomics in understanding metabolic states and the biochemical processes that influence cells and biological systems. Metabolomics, the study of metabolites in biological samples, is increasingly recognized as a valuable tool in a variety of applications, from disease biomarker discovery to drug development.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5366
Market Trends Driving Growth
One of the key drivers for the market’s expansion is the technological advancements in mass spectrometry. In June 2023, the American Society for Mass Spectrometry (ASMS) in collaboration with Waters Corporation, announced updates to its SELECT SERIES MRT System. These updates improve the resolution and usability of UPLC-MS/MS metabolomics and drug discovery applications. The new system offers a 50% increase in resolution, enabling 300,000 FWHM resolution and 3x faster scan speeds, thereby accelerating research and improving the accuracy of results. As metabolomics technologies continue to evolve, they enable deeper insights into biological processes, which in turn supports the development of more effective treatments and therapies.
The development of high-resolution mass spectrometers (MS) is another key trend. These next-generation systems combine proteomics, metabolomics, biopharmaceutical characterization, and small molecule analysis with the performance needed for both research and high-throughput analysis. This capability is critical for enhancing accuracy, simplifying operations, and accelerating business outcomes, which collectively contribute to the growth of the metabolomics market.
Another notable contributor to market growth is Horizon Europe, the EU's research and innovation funding program, which has a budget of €93.5 billion for the 2021-2027 period. Horizon Europe provides funding for projects in the metabolomics field, fostering innovation and advancements in the sector.
Moreover, Canada's national metabolomics laboratory, TMIC, plays an instrumental role in providing top-tier services in metabolomics analysis. This includes providing analytical/quantitative services and bioinformatics support to Canadian researchers and businesses, further promoting the development of the metabolomics market.
Metabolomics is also gaining attention as a potential tool for discovering biomarkers of diseases like diabetes and its complications. Metabolites, being the final products of cellular processes, can offer vital clues regarding the onset and progression of diseases, making them invaluable for diagnostics and therapeutic development.
Recent Developments in the Metabolomics Market
The metabolomics market continues to witness strategic partnerships and acquisitions, further driving its growth. For instance, in September 2024, Trinity Biotech, a commercial-stage biotechnology company, acquired Metabolomics Diagnostics, an Irish company specializing in novel biomarker development. This acquisition strengthens Trinity Biotech’s position in the field of diagnostics and diabetes management.
In May 2024, Metabolon, Inc., a global leader in metabolomics solutions, unveiled significant improvements to its services, including a new 4-week project turnaround time. This improvement makes it easier for clients to access accurate metabolomics data faster, thus supporting faster decision-making in research and drug development.
Additionally, in June 2022, Ginkgo Bioworks acquired assets from Bitome, a company specializing in point-of-care metabolite testing. This acquisition helps accelerate bioproduct development, particularly by using machine learning to monitor cell culture media, which optimizes bioprocesses and facilitates more efficient biomanufacturing.
领英推荐
Furthermore, in August 2024, Metabolon entered into a partnership with the Scottish Early Rheumatoid Arthritis (SERA) Research Study to investigate how mild rheumatoid arthritis biomarkers can predict disease risk, progression, and response to therapy.
Collaborations between major companies are also proving beneficial for the industry. In June 2024, 23andMe Holdings and Nightingale Health announced a collaboration to test the efficacy of Nightingale Health’s blood metabolomics panel using a cohort of 23andMe members. This collaboration aims to validate the potential of metabolomics in preventive care and treatment.
Key Companies in the Metabolomics Market
The metabolomics market is home to several top companies that provide cutting-edge solutions in the field. Some of the key players include:
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/metabolomics-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5366
We’ve prepared a service to support you. Please feel free to contact us at? [email protected]
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.dhirubhai.net/company/towards-healthcare